
Hodgkin lymphoma is a lymphatic malignancy. The lymphatic system is part of the body's immune system, which fights germs and diseases. Hodgkin lymphoma develops when healthy cells in the lymphatic system mutate and expand out of control.
The lymphatic system contains lymph nodes. They are located throughout the body. Most lymph nodes are in the abdomen, groin, pelvis, chest, underarms, and neck.
The lymphatic system contains the spleen, thymus, tonsils, and bone marrow. Hodgkin lymphoma can affect all these locations and other organs in the body.
Hodgkin lymphoma, formerly known as Hodgkin disease, is one of two primary forms of lymphomas. The other is non-Hodgkin's lymphoma.
The most frequent initial symptom of Hodgkin lymphoma is painless enlarged lymph nodes in the neck, underarm, or groin. Additional symptoms include:
There are four classical Hodgkin lymphoma subtypes:
Disease staging assists healthcare providers in determining how advanced the disease is, how quickly it may spread, and which treatments may be most effective. Here are the phases of Hodgkin lymphoma.
Causes
Risk Factors
The following factors can raise the risk of Hodgkin lymphoma:
Complications
Complications of Hodgkin lymphoma (HL) can include:
Here are some preventative tips for Hodgkin Lymphoma (HL):
While these strategies may not ensure prevention, they promote general health and early intervention.
Chemotherapy: This typical Hodgkin lymphoma treatment employs one or more medications to kill or prevent cancer cells from growing. Providers may utilise one or more types of chemotherapies.
Cost Start From USD 7420 - USD 30000Explore Options
Radiation therapy: This therapy employs high-powered laser beams to kill cancer cells in afflicted lymph nodes or areas of malignant dissemination. It is frequently used with chemotherapy for early-stage Hodgkin lymphoma treatment.
Immunotherapy: This treatment strengthens your immune system, making it more effective in identifying and eliminating cancer cells. Checkpoint inhibitors are a key immunotherapy treatment for Hodgkin lymphoma.
Cost Start From USD 7420 - USD 42500Explore Options
Targeted therapy: It is the employment of medications or other substances to attack cancer cells. This treatment employs laboratory-created antibodies that are linked to chemotherapeutic medicines. They identify and eliminate cancer cells.
Cost Start From USD 7500 - USD 12000Explore Options
Bone Marrow Transplant: A bone marrow transplant, also known as a bone marrow stem cell transplant, involves introducing healthy bone marrow stem cells into the body. These cells restore damaged cells caused by chemotherapy and other treatments. If Hodgkin's lymphoma reappears or does not respond to conventional therapies, a bone marrow transplant may be a viable alternative.
Cost Start From USD 50000 - USD 80000Explore Options
Rehabilitation for Hodgkin Lymphoma (HL) focuses on assisting patients in recovering physically, emotionally, and cognitively during and after therapy. Key rehabilitation options include:
MediGence can assist and guide you in selecting the best physician and medical facility for your care.
Depending on the circumstances, your doctor may prescribe medication to assist you in managing your symptoms and support your treatment plan.
Treatment regimens are adapted to the patient's specific cancer stage and location.









Istanbul, Turkey
Medicana Camlica Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:

Istanbul, Turkey
Architecture of the Hospital designed as per the comfort of patients-

Istanbul, Turkey
Acibadem Kadikoy Hospital located in Istanbul, Turkey is accredited by JCI. Also listed below are some of the most prominent infrastructural details:
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are some of the reasons for choosing Turkey:
Yes, Hodgkin lymphoma is highly treatable and often cured, mainly if found early. Treatments typically include chemotherapy, radiation therapy, or a combination of the two. Turkey's survival rates are comparable to global averages, especially for early-stage disorders.
Treatments typically include chemotherapy, radiation therapy, or a combination of the two. The most common chemotherapy treatment. Stem cell transplants may be considered in the advanced stages or following a recurrence.
In Turkey, 5-year overall survival rates for Hodgkin lymphoma (HL) range from 84% to 90%, according to recent studies. Survival rates are influenced by illness stage at diagnosis, the existence of symptoms, and laboratory results such as albumin levels. Early-stage patients with good prognostic variables typically have better outcomes.
In Turkey, non-Hodgkin lymphoma is more common than Hodgkin lymphoma (HL). A study at a Turkish tertiary center discovered that HL accounted for about 20% of the cases, whereas NHL accounted for the other 80%. This distribution is consistent with global trends, in which NHL occurs more frequently than HL.
Standard treatment side effects include nausea, hair loss, exhaustion, infections, and organ damage caused by chemotherapy or radiation. Long-term follow-up is required to monitor for any residual effects.
Hodgkin lymphoma (HL) treatment in Turkey has achieved high success rates, with many patients attaining complete remission. Studies report 5-year overall survival rates ranging from 84% to 99% and event-free survival rates between 77% and 90%. These outcomes align with global standards, highlighting the effectiveness of early detection and modern therapies in the Turkish healthcare system, including chemotherapy and radiation.
Yes, there are ongoing research and clinical trials for Hodgkin lymphoma in Turkey, including collaborations with international institutes and an emphasis on early-phase oncology drug trials and cancer genomics.